Insulin Drugs Global Market Sees Growth Rate Of 13% Through 2022

20 May, 2022

The global insulin drugs market size is expected to grow from $28.82 in billion 2021 to $32.51 billion in 2022 at a compound annual growth rate (CAGR) of 12.8%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global insulin drug market size is expected to reach $49.71 billion in 2026 at a CAGR of 11.2%.

What is the Global Insulin Drugs Market?

The insulin drugs market consists of manufacturers’ sales of insulin drugs and types of Insulin by entities (organizations, sole traders and partnerships) which are used to treat diabetes. Insulin is a medication prescribed to treat type 1 diabetes and type 2 diabetes mellitus. There are several types, preparations, and dosage amount of insulin. Insulin is a hormone that is produced naturally in our bodies. Its main role is to allow cells throughout the body to uptake glucose (sugar) and convert it into a form that can be used by these cells for energy. The market covered in this report does not include non-insulin drugs and other antidiabetic drugs or medicine.

Get a Sample of the global insulin drugs market report

What drives the Global Insulin Drugs Market?

Changing lifestyles are leading to a higher prevalence of diabetes. This is expected to drive the demand for diabetes drugs during the forecast period. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of diabetes. According to a study, there was a high prevalence of diabetes in people with sedentary lifestyles. Additionally, people suffering from obesity are up to 80 times more likely to develop type 2 diabetes. According to a World Health Organization (WHO) report, 74% of men and 64% of women in the UK, for instance, are expected to be overweight by 2030. These factors are expected to increase the patient pool of diabetes, thereby likely to drive the diabetes therapies market during the forecast period.

Get the full global insulin drugs industry report here

Global Insulin Drugs Market Segments
The global insulin drugs market is segmented:
By Product Type: Prandial Insulins, Basal Insulins, Premixed Insulins, Others
By Application: Type II Diabetes, Type I Diabetes, Gestational Diabetes, Prediabetes
By Drug Classification: Branded Drugs, Generic Drugs
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drugs Stores, Others
By Geography: The regions covered in the insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Insulin Drugs Global Market Report 2022 provides market size and growth forecasts for the global insulin drugs market, global insulin drugs market share, insulin drugs market segments and geographies, insulin drugs market competitive landscape including leading competitors’ revenues, profiles and market shares. The insulin drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Global Insulin Drugs Industry Players include Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, NovoRapid/Novolog, Actrapid, Admelog, Novolin/Actrapid/Insulatard, Ryzodeg, Sanofi, Soliqua/Suliqua, Toujeo, Tresiba and Xultophy. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.